Navigation Links
New Patient Satisfaction Study With budesonide/formoterol Combination Therapy and fluticasone/salmeterol Combination Therapy in Adults With Asthma
Date:5/20/2008

s are working and self-management of dosing, as well as seven other related categories(1). The assessment of overall satisfaction was based on all the eleven ATSM items.

About the Study Design (Abstract A13)

Patient satisfaction was assessed in an open-label study involving 832 patients ages 18 years and older with moderate to severe asthma who were previously treated with ICS(1). After a 10-14 day run-in on previous ICS therapy, patients were randomized 2:1 to receive twice daily treatment with two inhalations of budesonide/formoterol combination therapy pressurized metered-dose inhaler (pMDI) fixed dose at 160/4.5 micrograms (mcg) (N=698) or twice daily treatment with one inhalation of fluticasone/salmeterol combination therapy dry powder inhaler (DPI) at 250/50 mcg (N=350)(1). After one month, patients on budesonide/formoterol combination therapy pMDI fixed dose were randomized 1:1 to continue budesonide/formoterol combination therapy pMDI fixed dose (N=333) or budesonide/formoterol combination therapy adjustable dose (N=330) at either once daily treatment with two inhalations of 160/4.5 mcg, twice daily treatment with two inhalations of 160/4.5 mcg, or twice daily treatment with four inhalations of 160/4.5 mcg for six months. The patients originally treated with fluticasone/salmeterol combination therapy remained on that medication (N=335)(1).

About SYMBICORT

SYMBICORT is a combination therapy indicated for the long-term maintenance treatment of asthma in patients 12 years of age and older(2). Administered twice daily, SYMBICORT is a combination of two proven asthma medications -- budesonide, an inhaled corticosteroid (ICS), and formoterol, a rapid and long- acting beta2-agonist (LABA)(2). SYMBICORT does not replace fast-acting inhalers and should not be used to treat acute symptoms of asthma(2).

Important Safety Information

Long acting beta2-adrenergic agonists may increase the risk of asthma- related death. Therefore,
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Asthma Patients Not Adequately Controlled on ICS Alone More Likely to Benefit From Advair(R) Than Doubling the Dose of ICS
2. Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease
3. Boston Scientific Announces Program to Analyze Latitude(R) Patient Monitoring Data
4. Stable Stroke Patients More Likely to Die From a Nonstroke Cardiovascular Event Than a Further Stroke
5. Top Cancer Hospitals in Denmark and Netherlands First in Europe to Treat Patients With RapidArc(TM) Radiotherapy
6. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Combination REOLYSIN(R)/Cyclophosphamide Trial
7. Edwards Lifesciences Celebrates One Million Heart Valve Patients and More at AATS 2008
8. CBI and PharmaVoice Announce Recipients of the Strategic Patient Adherence Awards
9. Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
10. Signalife Awarded New U.S. Patent, System For, And Method Of, Monitoring Heartbeats Of A Patient
11. Atherotech VAP Cholesterol Test Meets Updated ADA, ACC Measurement and Treatment Guidelines for High Risk Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... GLASGOW, Scotland , September 17, 2014 ... a new mode of action from a ... a decade  MGB Biopharma, a ... of anti-infectives, announces today that it has ... of its lead antibacterial, MGB-BP-3, against a ...
(Date:9/16/2014)... September 16, 2014 “Nature has developed, ... features that we desire in optical design,” said Joseph ... State University. “As we explore surfaces and structures at ... lessons were presented in San Diego in August during ... in Nature ” chaired by Shaw and Rongguang Liang ...
(Date:9/16/2014)... WASHINGTON, D.C., September 16, 2014 --The emerging field ... portable to the next level, enabling the construction ... highly efficient devices, individual molecules would take on ... and transistors. , A team of researchers from ... potential candidate for use in small-scale electronics: a ...
(Date:9/16/2014)... 16, 2014 Cardioxyl Pharmaceuticals, Inc. ... been shown to be effective in animal models following ... to intravenous infusions that could pave the way for ... presented yesterday at the Heart Failure Society of America,s ... Las Vegas . The research, ...
Breaking Biology Technology:MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 2MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 3MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 4MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 5MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 6MGB Biopharma Secures £4.0m ($6.4m) to Advance its Novel Lead Antibacterial, MGB-BP-3, into Clinical Development 7Nature’s designs inspire research into new light-based technologies 2Nature’s designs inspire research into new light-based technologies 3Nature’s designs inspire research into new light-based technologies 4Nature’s designs inspire research into new light-based technologies 5The future face of molecular electronics 2Cardioxyl Presents Oral Heart Failure Treatment Data For Its Experimental HNO Prodrug At HFSA 18th Annual Scientific Meeting 2
... the University of Pennsylvania have developed nanowires capable ... retrieving that data a thousand times faster than ... and micro-drives, all using less power and space ... professor in the Department of Materials Science and ...
... 3SBio Inc.,(Nasdaq: SSRX ), a leading China-based ... biopharmaceutical,products, will present at the UBS Global Life ... 2007 at 10:30 AM EST. The presentation ... on the Events,section of the investors page of ...
... Sept. 17 Warner Chilcott,Limited (Nasdaq: WCRX ) ... non-final Action Closing Prosecution from the U.S. Patent and,Trademark ... a,reexamination of LEO,s US Patent No. 6,753,013 (the "013 ... The 013 Patent covers TACLONEX,and certain of LEO,s products ...
Cached Biology Technology:Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster 2Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster 3Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent 2Warner Chilcott Announces New Information in USPTO Reexamination of Taclonex Patent 3
(Date:9/17/2014)... on a Carnegie expedition in Australia,s Great Barrier Reef ... since the mid-1970s. The scientists suggest that ocean acidification ... slowdown. , In a quest for historical context ... current measurements of the growth rate of a section ... more than 30 years ago. Their work is published ...
(Date:9/17/2014)... of bacterial infections, including MRSA and MSSA could ... bumps that mimic the scaly surface of shark ... access journal Antimicrobial Resistance and Infection Control ... materials prevented the spread of human disease bacteria ... Sharklet, is an arrangement of ridges formulated to ...
(Date:9/16/2014)... Hopkins neuroscientists have discovered the "molecular brakes" that time ... cochleas of mice. These "hair cells" translate sound waves ... and are interpreted as sounds. If the arrangement of ... A summary of the research will be published in ... , "The proteins Hey1 and Hey2 act as brakes ...
Breaking Biology News(10 mins):Coral growth rate plummets in 30-year comparison 2Sharks' skin has teeth in the fight against hospital superbugs 2Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2
... must account for the complexity of the human impact ... and temporal scales. "Scale-sensitive research" emerges as a new, ... analyses, and tools to the scale in which these ... that the decisions they take resolve ecological problems at ...
... role in successful foraging for southern elephant seals, a ... the open access journal PLOS ONE ., The ... the diving behaviour of four female southern elephant seals ... with light detectors. The researchers found that increased bioluminescence ...
... www.ucr.edu ) Researchers at the University of California, ... and Technology (CE-CERT) are working with the state of ... renewable biofuels. This research supports several California legislative ... of renewable fuels and reduce greenhouse gases. These include ...
Cached Biology News:Scientists call policy-makers to be scale-aware 2Scientists call policy-makers to be scale-aware 3UC Riverside developing biofuel formulations for California 2UC Riverside developing biofuel formulations for California 3
... is a personal desktop unit ideal for use ... , Rotation speed set at 12 rpm ... C , Bottle capacity of four 35 ... ml conical ,plastic bottles , Consistent, repeatable ...
... The SC250 Express is the latest edition ... SC250 Express has an extra large diameter ... The digital display panel allows precise setting ... Large chamber for handling large quantities and ...
... a no-frills, basic SpeedVac concentrator designed for ... this unit still features a standard Teflon ... of time and heat. It is designed ... a wide variety of different rotors for ...
... RC Maxi MB (for aqueous, other low ... evaporator systems respond to specific applications of ... safe concentration of heat-labile samples. The RC ... of cold traps and a wide selection ...
Biology Products: